Fair value · Abivax S.A. (AAVXF) · updated 2026-09-21 · from annual report FY2025
Abivax trades at $139.00. We are not reading assumptions out of that price: financials are filed in EUR; our prices are in USD, so these methods need a conversion we do not yet publish.
Everything below is unaffected: the filed statements, the filing they came from, and AAVXF’s growth history are all as reported.
The filing behind these numbers
Abivax S.A.- Revenue
- EUR 0
- Diluted EPS
- EUR -4.83
- Free cash flow
- EUR -161.3M
- operating cash flow − capital expenditure
- Diluted shares
- 69.5M
- weighted average
annual report FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-23 · accession 0001956827-26-000012
Open this filing on sec.govNeed AAVXF data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.